Skip to main content

Table 1 The clinical characteristics of the study subjects

From: The function and morphology of Meibomian glands in patients with thyroid eye disease: a preliminary study

 

TED group

(31 eyes of 17 patients)

Non-TED group

(31 eyes of 17 controls)

P value†

Age (yr)

44.7 ± 11.0

44.7 ± 11.2

0.785

CAS

1.6 ± 0.7

–

–

Disease duration (months)

47.3 ± 63.5

–

–

Exophthalmos (mm)

20.4 ± 4.3

16.5 ± 1.1

<  0.001*

Lagophthalmos (mm)

0.9 ± 1.9

0.0 ± 0.0

0.015*

Partial blinking rate (%)

58.4 ± 34.7

55.1 ± 34.1

0.702

ST-1 (mm)

12.6 ± 9.0

13.0 ± 10.2

0.885

SPEED (score)

7.4 ± 4.1

6.8 ± 4.7

0.509

MG dysfunction signs‡ (eyes)

27

1

<  0.001*

MGd (score)

2.1 ± 0.9

2.2 ± 0.9

0.555

MGE (score)

0.6 ± 1.1

0.8 ± 0.9

0.379

MGYLS (score)

4.7 ± 3.1

3.0 ± 2.5

0.014*

TMQS (score)

10.1 ± 8.0

8.5 ± 4.9

0.412

LLT (nm)

74.1 ± 21.7

72.0 ± 21.9

0.654

  1. †Fisher’s exact test was used to test the between-group differences in MG dysfunction signs, while the Wilcoxon signed-rank test was used to test other parameters
  2. (*) Statistically significant (P < 0.05)
  3. ‡MG dysfunction signs, signs of meibomian gland (MG) dysfunction, including irregular lid margin, vascular engorgement, plugged meibomian gland orifices, and displacement of mucocutaneous junction
  4. CAS Clinical activity score, ST-1 Schirmer test 1, SPEED Scores of SPEED questionnaire, MGd MG dropout, MGE MG expressibility, MGYLS MG yielding liquid secretion, TMQS Total meibum quality score, LLT Lipid layer thickness
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us